Evaluating Disparities in High-Grade Glioma Presentation

High-grade gliomas represent aggressive, life-threatening central nervous system malignancies that demand prompt diagnosis and multidisciplinary intervention. However, clinical patterns at initial presentation often differ significantly across diverse sociodemographic backgrounds. A multi-institutional retrospective cohort investigation analyzed 314 adult patients treated across three academic medical centers. The cohort comprised 173 White patients and 144 non-White individuals, including Black, Hispanic, and Asian patients. Researchers sought to elucidate how racial and ethnic backgrounds influence the initial high-grade glioma presentation. Notably, multivariate analyses revealed that White patients presented at an older median age compared to non-White cohorts. Importantly, this age disparity remained significant even after controlling for isocitrate dehydrogenase 1 mutation status. In contrast, minority patients regularly sought hospital medical evaluation at younger ages. Furthermore, their disease manifested with distinct clinical profiles. These findings challenge the conventional assumption that symptom manifestation reflects only tumor biology or anatomical lesion distribution. Instead, sociodemographic factors, socioeconomic status, and environmental variables intersect to shape the exact clinical trajectory. Consequently, recognizing these demographic nuances allows clinicians to detect intracranial neoplasms earlier. Physicians must therefore remain vigilant when evaluating patients across all cultural and socioeconomic backgrounds.

Clinical Symptom Divergence Across Patient Demographics

The initial clinical manifestations of high-grade gliomas vary substantially across patient populations. For example, White patients presented significantly more frequently with cognitive deficits than non-White patients. In the multicenter cohort, 42.3 percent of White patients reported noticeable memory loss, executive dysfunction, or subtle behavioral shifts. Conversely, only 21.1 percent of non-White patients presented with cognitive concerns. Subtle neurocognitive deficits often permit outpatient evaluation before acute neurological crisis occurs. In contrast, Black and Hispanic patients presented with far more acute and dramatic events. Specifically, Black patients were significantly more likely to present with sudden syncope. In fact, 15.8 percent of Black patients experienced syncopal episodes, compared to only 2.3 percent of other cohorts. Similarly, Hispanic patients demonstrated a remarkably higher incidence of seizures at initial diagnosis. Approximately 35.7 percent of Hispanic individuals experienced new-onset seizures, compared to 15.9 percent of non-Hispanic patients. Consequently, these acute manifestations frequently brought minority patients into emergency departments rather than routine outpatient clinics. These presentation patterns underscore the diverse clinical paths that patients travel before confirmation of an intracranial malignancy. Therefore, clinicians must treat new-onset unprovoked seizures or unexplained syncope in younger adults as potential red flags for intracranial neoplasms.

Neuroimaging Disparities: Mass Effect and Midline Shift

Beyond clinical symptomatology, baseline neuroimaging examinations demonstrated striking anatomical and structural differences between racial groups. In particular, non-White patients exhibited significantly higher rates of marked intracranial mass effect on baseline magnetic resonance imaging. Approximately 76.1 percent of non-White patients displayed pronounced mass effect, compared to 59.8 percent of White patients. Furthermore, non-White individuals demonstrated nearly double the frequency of midline shift upon initial presentation. Specifically, midline shift occurred in 49.3 percent of non-White patients, whereas it appeared in only 32.5 percent of White patients. These anatomical markers directly indicate advanced local progression and substantial surrounding vasogenic edema. Consequently, these structural distortions place patients at immediate risk of brain herniation syndromes, uncal compromise, and intracranial hypertension. Moreover, severe mass effect complicates operative resection, restricting the neurosurgeon's ability to achieve safe gross total resection. Elevated intracranial pressures also require aggressive preoperative stabilization using osmotic agents and high-dose dexamethasone. Because midline shift correlates with higher perioperative morbidity and poorer overall functional outcomes, these radiological disparities hold profound prognostic relevance. Hence, structural discrepancies on presentation imaging indicate that minority patients frequently enter tertiary neurosurgical care with more advanced disease burden.

Socioeconomic Drivers of Delayed Neurological Diagnosis

Why do profound disparities exist in the initial presentation of high-grade gliomas? Biological variations may influence tumor growth kinetics, but socioeconomic drivers provide a compelling clinical explanation. Patients with higher socioeconomic status, robust health literacy, and comprehensive health insurance typically access outpatient primary care more readily. Consequently, family members and clinicians recognize subtle cognitive changes or mild executive deficits early. In contrast, socially vulnerable populations frequently encounter substantial barriers to healthcare. These obstacles include financial strain, lack of health insurance, limited transportation, and reduced access to neurological specialists. As a result, early symptoms such as episodic headaches, mild mood changes, or slight word-finding difficulties remain unaddressed. Without intervention, high-grade gliomas double in cellular volume rapidly and incite substantial peritumoral edema. Therefore, disease often remains undetected until acute decompensation forces an emergency room encounter. Sudden syncope, status epilepticus, or profound neurological deficits then compel urgent computed tomography or magnetic resonance imaging. Socioeconomic vulnerability indexes consistently correlate with such diagnostic delays across oncological cohorts. Thus, systemic healthcare inequities fundamentally alter the clinical timeline, transforming manageable outpatient presentations into life-threatening neurosurgical crises.

Actionable Strategies for Acute Care and Early Detection

Addressing these presentation disparities requires concrete clinical and systemic interventions across health systems. First, emergency physicians and primary care providers must maintain high clinical suspicion for intracranial neoplasms. When evaluating adult patients presenting with first-time syncope, clinicians should not assume cardiac etiology without considering structural neurological causes. Similarly, healthcare providers must evaluate any adult presenting with new-onset seizures using immediate neuroimaging. In addition, health systems must reduce barriers that prevent vulnerable communities from obtaining timely advanced imaging. Outpatient clinics should establish expedited referral pathways to neurology and neuro-oncology for patients exhibiting progressive cognitive or behavioral changes. Furthermore, community outreach and public health education should highlight non-specific neurological warning signs. Educating families regarding persistent morning headaches, subtle personality shifts, and unprovoked falls empowers earlier medical consultation. Within hospitals, multidisciplinary neuro-oncology boards must implement standardized intake protocols to identify social vulnerabilities. Navigators and social workers can immediately connect newly diagnosed patients with vital financial and logistical support. Ultimately, proactive diagnostic pathways and equitable care access will prevent delayed presentation, lower emergency admissions, and improve survival outcomes for all patients facing aggressive brain malignancies.

Frequently Asked Questions

How does high-grade glioma presentation differ among demographic groups?

Studies show minority patients often present with acute, severe symptoms such as seizures or syncope. In contrast, White patients more frequently present with subtle cognitive changes at an older age. In addition, minority populations demonstrate higher rates of significant midline shift and pronounced intracranial mass effect on baseline neuroimaging.

Why do certain patient cohorts present with greater midline shift?

Disparities in midline shift typically stem from prolonged diagnostic delays and systemic barriers to healthcare access. When individuals lack timely neurological evaluations, invasive intracranial tumors expand unchecked. Consequently, progressive peri-tumoral edema and mass effect accumulate over time, culminating in structural brain displacement and emergency department presentations with critical neurological decompensation.

What diagnostic steps should clinicians prioritize for adult-onset seizures?

Clinicians must immediately order contrast-enhanced brain magnetic resonance imaging for any adult presenting with new-onset unprovoked seizures or unexplained syncope. Furthermore, prompt neurosurgical and neuro-oncological consultations should occur without delay. Early neuroimaging detects aggressive primary neoplasms before extensive edema, herniation, or irreversible focal neurological deficits develop.

Disclaimer: This content is for informational and educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Ghosh SR et al. The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysis. J Neurooncol. 2025 Jul. doi: 10.1007/s11060-025-05012-1. PMID: 40131577.


2. Lee JW, Wen PY, Hurwitz S, Black PM, Golby AJ, Kesari S. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010;67(3):336-342.


3. Gately L, Collins A, Murphy M, Dowling A. Symptom presentation and diagnostic intervals in high-grade glioma: a retrospective cohort study. Neurooncol Pract. 2020;8(1):78-86.